Clinical Saccharomyces cerevisiae isolates cannot cross the epithelial barrier in vitro

International Journal of Food Microbiology

Volumn 157, Issue 1, 2012, Pages 59-64

  Pérez Torrado, Roberto ^a   Llopis, Silvia ^a   Jespersen, Lene ^b   Fernández Espinar, Teresa ^a   Querol, Amparo ^a  

^a INSTITUTO DE AGROQUÍMICA Y TECNOLOGÍA DE ALIMENTOS CSIC   (Spain)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Clinical; Intestinal barrier; Saccharomyces cerevisiae; Yeast

Indexed keywords

ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CELL ADHESION; CONTROLLED STUDY; CYTOTOXICITY; FUNGAL STRAIN; FUNGAL VIRULENCE; FUNGUS GROWTH; FUNGUS ISOLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTESTINE EPITHELIUM CELL; SACCHAROMYCES CEREVISIAE;

CACO-2 CELLS; CANDIDA ALBICANS; CANDIDA GLABRATA; DIETARY SUPPLEMENTS; FOOD SAFETY; HUMANS; INTESTINAL MUCOSA; SACCHAROMYCES CEREVISIAE; YEASTS;

CANDIDA ALBICANS; CANDIDA GLABRATA; MURINAE; SACCHAROMYCES CEREVISIAE;

EID: 84861754366     PISSN: 01681605     EISSN: 18793460     Source Type: Journal    
DOI: 10.1016/j.ijfoodmicro.2012.04.012     Document Type: Article

References (36)

1. Byron K.V., Clemons J.K., McCusker J.H., Davis R.W., Stevens D.A. Pathogenicity of Saccharomyces cerevisiae in complement factor five-deficient mice. Infection and Immunity 1995, 63:478-485.
2. Clemons K.V., McCusker J.H., Davis R.W., Stevens D.A. Comparative pathogenesis of clinical and nonclinical isolates of Saccharomyces cerevisiae. Journal of Infectious Diseases 1994, 169:859-867.
3. Dalle F., Wachtler B., L'Ollivier C., Holland G., Bannert N., Wilson D., Labruere C., Bonnin A., Hube B. Cellular interactions of Candida albicans with human oral epithelial cells and enterocytes. Cellular Microbiology 2010, 12:248-271.
4. de Llanos R., Querol A., Planes A.M., Fernández-Espinar M.T. Molecular characterisation of clinical Saccharomyces cerevisiae isolates and their association with non-clinical strains. Systematic and Applied Microbiology 2004, 27:427-435.
5. de Llanos R., Fernandez-Espinar M.T., Querol A. A comparison of clinical and food Saccharomyces cerevisiae isolates on the basis of potential virulence factors. Antonie Van Leeuwenhoek 2006, 90:221-231.
6. de Llanos R., Llopis S., Molero G., Querol A., Gil C., Fernández-Espinar M.T. In vivo virulence of commercial Saccharomyces cerevisiae strains with pathogenicity-associated phenotypical traits. International Journal of Food Microbiology 2011, 144:393-399.
7. Deak T., Beuchat L. Handbook of spoilage yeasts 1996, CRC, Boca Raton.
8. Di Pasquale G., Chiorini J.A. AAV transcytosis through barrier epithelia and endothelium. Molecular Therapy 2006, 2006(13):506-516.
9. Enache-Angoulvant A., Hennequin C. Invasive Saccharomyces infection: a comprehensive review. Clinical Infectious Diseases 2005, 41:1559-1568.
10. Fröhlich-Wyder M.T. Yeasts in dairy products. Yeasts in Food. Beneficial and Detrimental Aspects 2003, 209-237. Behr, Hamburg. T. Boekhout, V. Robert (Eds.).
11. Groschwitz K.R., Hogan S.P. Intestinal barrier function: Molecular regulation and disease pathogenesis. The Journal of Allergy and Clinical Immunology 2009, 124:3-20.
12. Hazen K.C. New and emerging yeast pathogens. Clinical Microbiology Reviews 1995, 8:462-478.
13. Herbrecht R., Nivoix Y. Saccharomyces cerevisiae fungemia: an adverse effect of Saccharomyces boulardii probiotic administration. Clinical Infectious Diseases 2005, 40:1635-1637.
14. Jacques N., Casaregola S. Safety assessment of dairy microorganisms: the hemiascomycetous yeasts. International Journal of Food Microbiology 2008, 126:321-326.
15. Jensen D.P., David M.D., Smith M.D. Fever of unknown origin secondary to brewer's yeast ingestion. Archives of Internal Medicine 1976, 136:332-333.
16. Kalischuk L.D., Leggett F., Inglis G.D. Campylobacter jejuni induces transcytosis of commensal bacteria across the intestinal epithelium through M-like cells. Gut Pathogens 2010, 2:14.
17. Klingberg T.D., Lesnik U., Arneborg N., Raspor P., Jespersen L. Comparison of Saccharomyces cerevisiae strains of clinical and nonclinical origin by molecular typing and determination of putative virulent traits. FEMS Yeast Research 2008, 8:631-640.
18. Lherm T., Monet C., Nougiere B., Soulier M., Larbi D., Le Gall C., Caen D., Malbrunot C. Seven cases of fungemia with Saccharomyces boulardii in critically ill patients. Intensive Care Medicine 2002, 28:797-801.
19. Li L., Dongari-Bagtzoglou A. Epithelial GM-CSF induction by Candida glabrata. Journal of Dental Research 2009, 88:746-751.
20. Li L., Redding S., Dongari-Bagtzoglou A. Candida glabrata: an emerging oral opportunistic pathogen. Journal of Dental Research 2007, 86:204-215.
21. Lolis N., Veldekis D., Moraitou H., Kanavaki S., Velegraki A., Triandafyllidis C., Tasioudis C., Pefanis A., Pneumatikos I. Saccharomyces boulardii fungaemia in an intensive care unit patient treated with caspofungin. Critical Care 2008, 12:414.
22. Loureiro V., Malfeito-Ferreira M. Spoilage yeasts in the wine industry. International Journal of Food Microbiology 2003, 86:23-50.
23. Loureiro V., Querol A. The prevalence and control of spoilage yeasts in foods and beverages. Trends in Food Science and Technology 1999, 10:356-365.
24. Lulu L., Kashleva H., Dongari-Bagtzoglou A. Cytotoxic and cytokine-inducing properties of Candida glabrata in single and mixed oral infection models. Microbial Pathogenesis 2007, 42:138-147.
25. McCullough M.J., Clemons K.V., McCusker J.H., Stevens A.D. Species identification and virulence attributes of Saccharomyces boulardii (nom. Inval.). Journal of Clinical Microbiology 1998, 36:2613-2617.
26. McCusker J.H., Clemos K.V., Stevens D.A., Davis R.W. Saccharomyces cerevisiae virulence phenotype as determined with CD-1 mice is associated with the ability to grow at 42 °C and form pseudohyphae. Infection and Immunity 1994, 62:5447-5455.
27. Montineri A., Lacobello C., Larocca L., La Rosa R., Nigro L., Fatuzzo F. Saccharomyces cerevisiae fungemia associated with multifocal pneumonia in a patient with alcohol-related hepatic cirrhosis. Le Infezioni in Medicina 2008, 16:227-229.
28. Muñoz P., Bouza E., Cuenca-Estrella M., Eiros J.M., Perez M.J., Sanchez-Somolinos M., Rincon C., Hortal J., Pelaez T. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clinical Infectious Diseases 2005, 40:1625-1634.
29. Murphy A., Kavanagh K. Emergence of Saccharomyces cerevisiae as a human pathogen. Implications for biotechnology Review. Enzyme and Microbial Technology 1999, 25:551-557.
30. Naglik J.R., Moyes D.L., Wächtler B., Hube B. Candida albicans interactions with epithelial cells and mucosal immunity. Microbes and Infection 2011, (Jul 14).
31. Pontón J., Rüchel R., Clemons K.V., Coleman D.C., Grillot R., Guarro J., Aldebert D., Ambroise-Thomas P., Cano J., Carrillo-Muñoz A.J., Gené J., Pinel C., Stevens D.A., Sullivan D.J. Emerging pathogens. Medical Mycology 2000, 38:225-236.
32. Smith D., Metzgar D., Wills C., Fierer J. Fatal Saccharomyces cerevisiae aortic graft infection. Journal of Clinical Microbiology 2002, 40:2691-2692.
33. Sobel J.D., Schmitt C.A., Lynch M., Vazquez J., Zervos M. Emerging problem of vaginitis due to Saccharomyces cerevisiae. Clinical Infectious Diseases 1993, 16:93-94.
34. Swinne D., Van Nolard N., Rooij P., Detandt M. Bloodstream yeast infections: a 15-month survey. Epidemiology and Infection 2009, 137:1037-1040.
35. Williams J.S., Mufti G.J., Powell S., Salisbury J.R., Higgins E.M. Saccharomyces cerevisiae emboli in an immunocompromised patient with relapsed acute myeloid leukaemia. Clinical and Experimental Dermatology 2007, 32:395-397.
36. Yáñez A., Murciano C., Llopis S., Fernández-Espinar M.T., Gil M.L., Gozalbo D. In vitro and in vivo studies on virulence and host responses to Saccharomyces cerevisiae clinical and non-clinical isolates. The Open Mycology Journal 2009, 3:37-47.